New Research Reveals Key Mechanism in Melanoma Treatment Resistance
Researchers have uncovered a crucial signaling pathway that allows melanoma cells to resist targeted therapies. The findings reveal how cancer cells bypass treatment through Rac1-driven mechanisms that remain resilient even when key pathways are blocked.
Breakthrough in Understanding Melanoma Resistance
Scientists have identified a critical signaling pathway that enables melanoma cells to resist targeted therapies, according to recent research published in Oncogene. The study reveals how Vav1 and Rac1 proteins collaborate to create treatment-resistant cancer cells that can bypass BRAF and MEK inhibitors, which are commonly used to treat BRAF V600-mutant melanoma.
